共 53 条
- [1] McMurray JJ(2014)Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med. 371 993-1004
- [2] Packer M(2019)Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction N Engl J Med. 381 1609-1620
- [3] Desai AS(2019)B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF Trial J Am Coll Cardiol. 73 1264-1272
- [4] Gong J(2021)Impact of sacubitril-valsartan treatment on diastolic function in patients with heart failure and reduced ejection fraction High Blood Press Cardiovasc Prev. 22 3570-12
- [5] Lefkowitz MP(2021)Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload ESC Heart Fail. 36 e12435-314
- [6] Rizkala AR(2021)Sacubitril/valsartan improves diastolic function but not skeletal muscle function in a rat model of HFpEF Int J Mol Sci. 35 9-undefined
- [7] Solomon SD(2018)The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction Cardiovasc Ther. 29 277-undefined
- [8] McMurray JJV(2019)Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction Curr Med Res Opin. undefined undefined-undefined
- [9] Anand IS(2016)Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J Am Soc Echocardiogr. undefined undefined-undefined
- [10] Ge J(undefined)undefined undefined undefined undefined-undefined